ESMO Immuno-Oncology Congress 2019
Abstracts submission deadline: Tuesday 2 October 2019
The most influential oncology meeting in Europe, in partnership with the EACR.
IMPORTANT! Beware of fraudulent websites offering registration or accommodation!
There are many good reasons to become an ESMO member. Find out why you should join Europe's leading medical oncology society
Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates.
The ESMO-MCBS scale is a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
At ESMO Congress 2018 in Munich, Women's cancers Patients Guides were presented in a talk-format session.
19 Sep 2019
Evidence for efficacy is based on the results from the TITAN trial
18 Sep 2019
Combination treatment concerns patients with advanced endometrial carcinoma who progressed on prior systemic treatment and whose tumours are not MSI...
18 Sep 2019
An electronic nose that detects chemicals in the breath of lung cancer patients can identify with 85% accuracy those who will or will not respond to...
18 Sep 2019
Update! Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
13 Sep 2019
Provide your feedback on the administrative and bureaucratic burden in Clinical Research.
13 Sep 2019
Doxolipad, a hybrid medicine, contains the active substance doxorubicin
Barcelona, Spain
27 Sep
- 01 Oct
2019
Lisbon, Portugal
11 Oct
- 12 Oct
2019
Lugano, Switzerland
11 Oct
- 12 Oct
2019
Lugano, Switzerland
17 Oct
- 18 Oct
2019
Barcelona, Spain
21 Oct
- 22 Oct
2019
Valencia, Spain
25 Oct
- 26 Oct
2019
